Literature DB >> 3555582

Rationale for combination therapy.

L Hansson.   

Abstract

Cardiovascular morbidity and mortality is higher in treated hypertensive patients than in normotensive subjects of the same age, sex and from the same populations. A possible and logical explanation for this could be that arterial pressure in treated hypertensive patients usually is significantly higher than in matched normotensive subjects. For these reasons it would appear logical to identify a therapeutic goal in the treatment of hypertension: to obtain normotensive blood pressure levels. In order to obtain this goal, combined treatment with more than one antihypertensive drug would appear to be required. Therapeutic combinations consisting of an ACE-inhibitor plus a diuretic or an ACE-inhibitor plus a calcium antagonist constitute two examples of antihypertensive drug combinations that would appear to offer potent antihypertensive efficacy and good tolerability.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3555582      PMCID: PMC1386042          DOI: 10.1111/j.1365-2125.1987.tb03118.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  THE ROLE OF BLOOD-PRESSURE CONTROL IN PREVENTING COMPLICATIONS OF HYPERTENSION.

Authors:  M HAMILTON; E M THOMPSON; T K WISNIEWSKI
Journal:  Lancet       Date:  1964-02-01       Impact factor: 79.321

2.  Angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Authors:  C I Johnston; L Arnolda; M Hiwatari
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

3.  Relation between prognosis and the blood pressure before and during treatment of hypertensive patients.

Authors:  D G Beevers; J Johnston; B L Devine; F G Dunn; H Larkin; D M Titterington
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

4.  Angiotensin converting enzyme inhibition in clinical practice. A re-examination of stepped-care: a retrospective and a prospective.

Authors:  A Zanchetti
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

5.  Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.

Authors:  A Amery; W Birkenhäger; P Brixko; C Bulpitt; D Clement; M Deruyttere; A De Schaepdryver; C Dollery; R Fagard; F Forette
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

6.  Malignant hypertension--improving prognosis in a rare disease.

Authors:  T Gudbrandsson; L Hansson; H Herlitz; L Andrén
Journal:  Acta Med Scand       Date:  1979

7.  Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care.

Authors:  O Samuelsson
Journal:  Acta Med Scand Suppl       Date:  1985

8.  Captopril or atenolol in essential hypertension.

Authors:  L Andrén; A Svensson; L Hansson
Journal:  Acta Med Scand Suppl       Date:  1983

9.  Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients.

Authors:  J Staessen; R Fagard; P Lijnen; L J Verschueren; A Amery
Journal:  Am Heart J       Date:  1983-08       Impact factor: 4.749

10.  Mortality in patients of the Glasgow Blood Pressure Clinic.

Authors:  C G Isles; L M Walker; G D Beevers; I Brown; H L Cameron; J Clarke; V Hawthorne; D Hole; A F Lever; J W Robertson
Journal:  J Hypertens       Date:  1986-04       Impact factor: 4.844

View more
  4 in total

Review 1.  Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?

Authors:  D A Sica
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 2.  Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects?

Authors:  A M MacConnachie; D Maclean
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

3.  Chronic antihypertensive treatment with captopril plus hydrochlorothiazide improves aortic distensibility in the spontaneously hypertensive rat.

Authors:  J M Chillon; C Capdeville-Atkinson; I Lartaud; J Guillou; P M Mertès; J Atkinson
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

4.  The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics.

Authors:  A G Dupont; D F Schoors; R P Venuti
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.